EICHOR
● Active Not Recruiting
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
Condition: Non-small Cell Lung Cancer · Sponsor: EMD Serono Research & Development Institute, Inc.
About this study
This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (179)
| Yuma Regional Medical Center | Yuma, Arizona, United States | — |
| Compassionate Care Research Group Inc - Edinger Medical Group, Inc. | Fountain Valley, California, United States | — |
| Memorial Care | Long Beach, California, United States | — |
| Ventura County Hematology Oncology Specialists | Oxnard, California, United States | — |
| Innovative Clinical Research Institute | Whittier, California, United States | — |
| Eastern Connecticut Hematology & Oncology Associates | Norwich, Connecticut, United States | — |
| Holy Cross | Fort Lauderdale, Florida, United States | — |
| Memorial Healthcare System | Hollywood, Florida, United States | — |
| Cancer Specialists of North Florida | Jacksonville, Florida, United States | — |
| Ocala Oncology | Ocala, Florida, United States | — |
| University Cancer and Blood Center | Athens, Georgia, United States | — |
| Hawaii Cancer Care | Honolulu, Hawaii, United States | — |
+ 167 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03940703